BioSpace News Archive

This round is led by Alethea Capital Management, LLC, with $3.5 million for Presidium to expand its physician-based services and to further its marketing programs.

Met primary and secondary endpoints in non-small cell lung cancer (NSCLC) Phase II clinical trial in patients previously treated with chemotherapy (cohort A)

Hansa Biopharma announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting on May 22, 2019 and has the following composition:

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Barclay “Buck” A. Phillips, an established life sciences executive, investor and entrepreneur, to its Board of Directors, effective November 14, 2019.

Medtronic plc announced financial results for its second quarter of fiscal year 2020, which ended October 25, 2019.

Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported that a new location has been authorized to become a PoNS Treatment™ Center in Canada bringing broader regional access to its innovative PoNS Treatment in the Toronto area.

CareDx, Inc. announced that Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will be participating in two upcoming investor conferences.

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the third quarter ended September 30, 2019 and provided a corporate update.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today reported its financial results and operational highlights for the third quarter ended September 30, 2019.

3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced it has received Orphan Drug Designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear in patients with microtia